Association analysis of polymorphisms in intron 2 of μ opioid receptor gene and effective dose in methadone maintenance treatment of heroin addiction

Abstract

Abstract: AIM: To explore the association between the single nucleotide polymorphisms (SNP) in intron 2 of the μ opioid receptor gene (OPRM1) and the effective dose in methadone maintenance treatment of heroin addiction.METHODS: The genotypes of the two SNPs (rs9479757, rs2075572) in 68 heroin dependent patients in methadone maintenance treatment were detected by TaqMan SNP genotyping technique, and the association between methadone dose and the two SNPs was analyzed.RESULTS: The frequencies of genotype and allele at rs9479757, rs2075572 were not significantly different between the high and low methadone dose groups (P>0.05). The average methadone daily dosages of various genotypes at the two SNPs were not significantly different (P>0.05).CONCLUSION: The polymorphisms (rs9479757, rs2075572) in intron 2 of the μ opioid receptor gene (OPRM1) may not play the major role in the effective dose in methadone maintenance treatment of heroin addiction.

Key words: μ opioid receptor, Gene polymorphism, Heroin, Methadone

CLC Number:

R969.8

XIE Xiao-hu, LIU Hui-fen, Zhang Ya-hai, CHEN Wei-sheng, ZHUANG Ding-ding, ZHANG Jian-bing, ZHOU Wen-hua. Association analysis of polymorphisms in intron 2 of μ opioid receptor gene and effective dose in methadone maintenance treatment of heroin addiction[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1081-1085.

References

[1] Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions[J]. Nat Rev Drug Discov, 2002, 1(9): 710-726.
[2] Booth RE, Corsi KF, Mikulich-Gilbertson SK. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users[J]. Drug Alcohol Depend, 2004, 74(2): 177-185.
[3] 胡蕾, 高利臣, 卓伟, 等. CYP450氧化还原酶的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2012, 17(7): 820-827.
[4] 陈冰, 蔡卫民, 杨婉花. CYP2D6基因多态性与抗精神病药物的个体化应用[J]. 中国临床药理学与治疗学, 2012, 17(9): 1067-1074.
[5] Li Y, Kantelip JP, Gerritsen-van Schieveen P, et al. Interindividual variability of methadone response: impact of genetic polymorphism[J]. Mol Diagn Ther, 2008, 12(2): 109-124.
[6] Crettol S, Besson J, Croquette-Krokar M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32(7): 1722-1727.
[7] Shi J, Hui L, Xu Y, et al. Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin[J]. Hum Mutat, 2002, 19(4): 459-460.
[8] Li T, Liu X, Zhu ZH, et al. Association analysis of polymorphism in the mu opioid gene and heroin abuse in Chinese subjects[J]. Addict Biol, 2000, 5(2): 181-186.
[9] 周文华, 杨国栋. 海洛因依赖:一种慢性脑病的临床治疗[J]. 中国药物滥用防治杂志, 2006, 12(5): 251-244.
[10] Kreek MJ, Borg L, Ducat E, et al. Pharmacotherapy in the treatment of addiction: methadone[J]. J Addict Dis, 2010, 29(2): 200-216.
[11] Zhang Z, Friedman PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use[J]. Addiction, 2003, 98(5): 673-684.
[12] Brown BS, Watters JK, Iglehart AS. Methadone maintenance dosage levels and program retention[J]. Am J Drug Alcohol Abuse, 1982, 9(2): 129-139.
[13] Blaney T,Craig RJ. Methadone maintenance:Does dose determine differences in outcome [J]? J Subst Abuse Treat, 1999, 16(3): 221-228.
[14] 谢小虎, 庄丁丁, 张亚海, 等. 海洛因成瘾者美沙酮维持治疗剂量的调查分析[J]. 中国药物滥用防治杂志, 2011, 17(6): 314-316.
[15] Levran O, Peles E, Hamon S, et al. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction[J]. Addict Biol, 2013, 18(4): 709-716.
[16] Oneda B, Crettol S, Bochud M, et al. β-Arrestin2 influences the response to methadone in opioid-dependent patients[J]. Pharmacogenomics J, 2011, 11(4): 258-266.